

# market announcement

For Public Release NZX Limited Wellington

30 June 2023

#### Results of Cannasouth Limited Annual Shareholder Meeting

At the Annual Shareholder Meeting of Cannasouth Limited (NZX:CBD) held in Hamilton on 30 June 2023 at the Ruakura Conference Centre, shareholders were asked to vote on two ordinary resolutions, which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by shareholders were:

### 1. Re-election of Mark Lucas as a Director of the Company

"That Mark Lucas be re-elected as a Director of the Company."

### 2. Appointment and Remuneration of Auditors

"That the Board is authorised to fix the remuneration of the Company's auditors, RSM Hayes Audit Limited, for the forthcoming year ending 31 December 2023."

The following are details of the total number of votes cast in person or by a proxy holder.

No.	Resolution	For	Against	Abstain
1	That Mark Lucas be re-elected as a Director of the Company.	126,018,050 99.88%	157,035 0.12%	71,820
2	That the Board is authorised to fix the remuneration of the Company's auditors, RSM Hayes Audit Limited, for the forthcoming financial year ending 31 December 2023.	125,894,713 99.93%	84,070 0.07%	268,122

-ENDS-

For further information visit <a href="www.cannasouth.co.nz">www.cannasouth.co.nz</a> or contact:

Mark Lucas

CEO / Executive Director

Email: mark.lucas@cannasouth.co.nz

Mobile: 021 484 649

**Colin Foster** 

CFO / Company Secretary

Email: colin.foster@cannasouth.co.nz

Mobile: 027 577 1498



## market announcement

#### **About Cannasouth Limited**

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <a href="https://www.cannasouth.co.nz/about/media/">https://www.cannasouth.co.nz/about/media/</a>